2
Clinical Trials associated with HS-20124 / Not yet recruitingPhase 1 注射用HS-20124 在晚期实体瘤受试者中的安全性、耐受性、药代动力学和有效性的I 期临床研究
[Translation] Phase I clinical study of the safety, tolerability, pharmacokinetics and efficacy of HS-20124 for injection in subjects with advanced solid tumors
评价HS-20124 在晚期实体瘤受试者中的安全性和耐受性
[Translation] To evaluate the safety and tolerability of HS-20124 in subjects with advanced solid tumors
A Phase I, Open-label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-20124 in Patients with Advanced Solid Tumors
HS-20124 is a novel DAR-8 antibody-drug conjugate (ADC) targeting CDH6. In preclinical studies, it inhibited tumor cell growth expressing CDH6 in vitro and in vivo. The first-in-human trial is conducted to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of HS-20124 in Patients With Advanced Solid Tumors.
100 Clinical Results associated with HS-20124
100 Translational Medicine associated with HS-20124
100 Patents (Medical) associated with HS-20124
100 Deals associated with HS-20124